fbpx
Cyber-wellness Means Cyber-awareRead more Addressing maternal mental healthcare in AfricaRead more Qatar v. Ecuador to kick off FIFA World Cup 2022™ on 20 NovemberRead more Webb Fontaine Announces Launch of Niger National Single Window (NNSW) to Bolster TradeRead more Ethiopia: Loan from United Nations Fund Allows Food and Agriculture Organization (FAO) to Scale Up Fertilizers for Farmers in TigrayRead more How Choosing the Right Printer Helps Small Businesses and Content Creators to Save Time, Maximise Productivity and Achieve GrowthRead more The United States Contributes USD $223 Million to Help World Food Programme (WFP) Save Lives and Stave Off Severe Hunger in South SudanRead more Eritrea: World Breastfeeding WeekRead more Eritrean community festival in Scandinavian countriesRead more IOM: Uptick in Migrants Heading Home as World Rebounds from COVID-19Read more

Moderna says infant Covid vaccine succeeded in trial

show caption
Moderna said it would submit authorization requests to the US Food and Drug Administration, European Medicines Agency and other global regulators for its Covid vaccine in children aged six months to six years./AFP
Print Friendly and PDF

Mar 24, 2022 - 11:06 AM

WASHINGTON — US biotech firm Moderna on Wednesday said it was pursuing regulatory approval for its Covid vaccine in children under six years old after the two-shot regimen was found to be safe and produced a strong immune response.

Specifically, two doses of 25 micrograms given to babies, toddlers and preschoolers generated similar levels of antibodies to two doses of 100 micrograms given to young people aged 18-25, indicating there would be similar levels of protection.

Children under six are the only age group that has yet to gain access to a Covid-19 vaccine in the United States.

Based on the data, Moderna said it would submit authorization requests to the US Food and Drug Administration (FDA), European Medicines Agency (EMA) and other global regulators in the coming weeks.

The results “are good news for parents of children under six years of age,” said CEO Stephane Bancel in a statement.

“We now have clinical data on the performance of our vaccine from infants six months of age through older adults.”

The company did however find relatively low vaccine efficacy against infection, with its trial taking place during the Omicron wave.

Vaccine efficacy in children six months up to age two was 43.7 percent, and efficacy was 37.5 percent in the two to five years age group.

The majority of these cases were mild and the two doses still provided very strong protection against severe outcomes. There were no hospitalizations or deaths.

Moderna said this was consistent with what had been observed among adults, and the company was evaluating a third dose as a booster, to increase efficacy against Omicron infection.

The trial included 4,200 aged two to six years and 2,500 aged six months to two years.

Side effects were generally mild and consistent with those seen in older age groups.

Rates of fever greater than 38 degrees Celsius (100.4 Fahrenheit) were around the same as commonly used and recommended pediatric vaccines: 17 percent in the six months to two years group, and 15 percent in the two years to six years group.

The company added that, after consulting with the FDA, it is also applying to be authorized among children six to 11 for two doses of 50 micrograms, and updating its application for authorization in kids aged 12 through 17.

The EMA and other regulators have already authorized the Moderna vaccine in these age groups.

Last month, the FDA postponed a meeting of a panel to consider the Pfizer-BioNTech Covid vaccine for children younger than five, saying it required additional data on third doses. The companies said they expected that data to be ready by April.

MAORANDCITIES.COM uses both Facebook and Disqus comment systems to make it easier for you to contribute. We encourage all readers to share their views on our articles and blog posts. All comments should be relevant to the topic. By posting, you agree to our Privacy Policy. We are committed to maintaining a lively but civil forum for discussion, so we ask you to avoid personal attacks, name-calling, foul language or other inappropriate behavior. Please keep your comments relevant and respectful. By leaving the ‘Post to Facebook’ box selected – when using Facebook comment system – your comment will be published to your Facebook profile in addition to the space below. If you encounter a comment that is abusive, click the “X” in the upper right corner of the Facebook comment box to report spam or abuse. You can also email us.